MAPT and supranuclear palsy, progressive, 1: The authors note that a limitation of the study relates to the somewhat controversial use of flortaucipir PET in PSP, as it was optimized for the paired helical tau fragments in Alzheimer’s and is known to have off-target binding in PSP.